Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition with function of treating cerebrovascular diseases

A composition and drug technology, applied in the field of medicine, can solve the problems of many adverse reactions, limited clinical use, high price and the like

Active Publication Date: 2014-07-23
HAINAN BIKAI PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although the clinically recommended antithrombotic drugs are effective, they have many adverse reactions and are expensive, which limits their clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition with function of treating cerebrovascular diseases
  • Pharmaceutical composition with function of treating cerebrovascular diseases
  • Pharmaceutical composition with function of treating cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] A pharmaceutical composition, comprising 19 g of ozagrel sodium and 1 g of 1,3-diaza-2,4-cyclopentadiene in the pharmaceutical composition.

[0091] The above pharmaceutical composition is used for treating thrombosis. The above pharmaceutical composition is used for treating acute thrombotic cerebral infarction and the movement disorder accompanied by cerebral infarction.

[0092] The above pharmaceutical composition is prepared into 1000 water injections or powder injections according to the prior art.

Embodiment 2

[0094] A pharmaceutical composition, comprising 19.2 g of ozagrel sodium and 0.8 g of 1,3-diaza-2,4-cyclopentadiene in the pharmaceutical composition.

[0095] The above pharmaceutical composition is used for treating thrombosis. The above pharmaceutical composition is used for treating acute thrombotic cerebral infarction and the movement disorder accompanied by cerebral infarction.

[0096] The above pharmaceutical composition is prepared into 1000 water injections or powder injections according to the prior art.

Embodiment 3

[0098] A pharmaceutical composition, comprising 19.6 g of ozagrel sodium and 0.4 g of 1,3-diaza-2,4-cyclopentadiene in the pharmaceutical composition.

[0099] The above pharmaceutical composition is used for treating thrombosis. The above pharmaceutical composition is used for treating acute thrombotic cerebral infarction and the movement disorder accompanied by cerebral infarction.

[0100] The above pharmaceutical composition is prepared into 1000 water injections or powder injections according to the prior art.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine and particularly relates to a pharmaceutical composition with function of treating cerebrovascular diseases. The pharmaceutical composition contains ozagrel sodium and 1, 3-diaza-2, 4-cyclopentadiene, wherein the weight percentage of the ozagrel sodium is more than or equal to 95 percent and less than 100 percent, and the weight percentage of the 1, 3-diaza-2, 4-cyclopentadiene is more than zero and less than or equal to 5 percent. The pharmaceutical composition provided by the invention is determined by pharmacology experiment and toxicology experiment.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing ozagrel sodium. Background technique [0002] A thrombus is a small piece of blood that forms on the surface of a vessel in the cardiovascular system where the lining has been peeled off or repaired. In variable flow dependent patterns, thrombus consists of insoluble fibrin, deposited platelets, accumulated leukocytes, and trapped red blood cells, and thrombosis is a process involving many genetic and environmental factors interacting with each other The process of multifactorial changes, clinically common patients with thrombosis diathesis, the most important features are family history, recurrent, young, severity of attack symptoms, and unusual site of thrombosis. Arterial or venous thrombosis or thromboembolism requires objective evidence. Angiography is the reference standard for diagnosis. Ultrasound detection with skillf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4174A61K31/4164A61P7/02A61P9/10A61P25/14
Inventor 陈容徐扬冯仲异史朝辉
Owner HAINAN BIKAI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com